News and Media

Publications and resources for members of the press.



Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America

NEW YORK., April 3, 2023 – Sumitovant Biopharma Ltd. (“Sumitovant”) announced today that its parent  company Sumitomo Pharma Co., Ltd. (“Sumitomo Pharma”) will combine its wholly owned U.S.  subsidiaries to form Sumitomo Pharma America, Inc. (“Sumitomo Pharma America”). Sumitomo Pharma  America will combine Sumitovant and its wholly owned U.S. subsidiaries, Myovant Sciences, Inc.,  Urovant Sciences, […]

Sumitovant Biopharma Completes Acquisition of Myovant Sciences

NEW YORK and BASEL, Switzerland, March 10, 2023 /PRNewswire/ — Sumitovant Biopharma Ltd. (“Sumitovant”) and Myovant Sciences Ltd. (“Myovant”) announced today that Sumitovant has successfully completed its acquisition of Myovant originally announced October 23, 2022. Sumitovant has acquired all outstanding shares of Myovant not already owned by Sumitovant in an all-cash deal with a total […]

Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022

Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 million Net product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022 Net product revenue from U.S. sales of […]



Economic burden of congenital athymia in the United States for patients receiving supportive care during the first 3 years of life

Congenital athymia is an ultra-rare pediatric condition characterized by the lack of thymus in utero and the naïve T cells critical for infection defense and immune regulation.

ELEVATE 2: A Multicenter Study of Rodatristat Ethyl in Patients with WHO Group 1 Pulmonary Arterial Hypertension

Rodatristat ethyl is a first in class prodrug for rodatristat, a potent inhibitor of tryptophan hydroxylase, the rate limiting enzyme in the biosynthesis of serotonin from dietary tryptophan.

Defining the Clinical, Emotional, Social, and Financial Burden of Congenital Athymia

This cross-sectional study of adult caregivers of patients with congenital athymia used both a quantitative survey and qualitative interviews. Caregivers of patients currently receiving supportive care responded to questions about the past 12 months.

About Us

United in our mission to deliver breakthrough medicines to patients faster, we make Sumitovant greater than the sum of our parts.

Get to Know Us

News from Sumitovant Portfolio Companies